Shares of Annovis Bio Inc. (ANVS) are surging over 122% in pre-market today, after the company announced that it has received Central Institutional Review Board or IRB approval to begin its Phase 2 clinical study in early PD and early AD patients at 15 sites across the US.
from RTT - Before the Bell https://ift.tt/31SYHdZ
via IFTTT
No comments:
Post a Comment